Safety Pharmacology Society
Email: Password:
  Forgot Your Password?
Follow us: Watch us on YouTube Follow Us on Twitter Find Us on LinkedIn
Back to Top

Continuing Education

View CE Agenda   (as of 9/25/15)

AM Courses


AM 1: Human Stem Cell Derived Cardiomyocytes: Emerging Technology to Guide Cardiac Safety Decisions during Preclinical Drug Development

Co-Chairs: Gary Gintant and Stefan Braam

The goal of the course is to provide attendees with an overview of basic principles and practical utility of stem cell derived cardiomyocytes in safety pharmacology. In this session the attendees will familiarize themselves with assays and technologies using these cells and implementation strategies in drug development. Speakers are experts from academia, technology companies and safety pharmacology professionals and regulatory agencies.

CE Book   (Registration Required)


AM 2: Making “Sense” of Sensory System Safety Pharmacology

Co-Chairs:  Matt Abernathy and Rachel Tapp

An imperative element in the safety assessment of all new molecular entities is the response of the central and peripheral nervous system including cranial and peripheral sensory pathways.  The requisite use of the functional observational battery and locomotor activity assessments by the current ICH Guideline directives (S7A) is considered to be the primary approach to the systematic monitoring of neurotoxic exposures.  The essential context for the adoption of acceptable assessment techniques is that the potential behavioral changes should have been identified and reliable measures of these changes should be included in further testing, if needed.  The current regulatory guidance limits non-clinical sensory system evaluation (sight, hearing, taste, smell, or touch) to those drugs of a known class with sensory system liability or use a non-traditional route of administration enabling contact with sensory epithelia.  The existing tiered level of drug evaluation leaves most drugs to enter the clinic with minimal information concerning the potential risk of sensory system liability.  In the case where a sensory system deficit is detected in non-clinical or clinical studies, Tier II evaluations must be conducted to fully characterize the observed toxicity and identify a therapeutic safety margin.  This continuing education course will focus on the core behavioral assays a safety pharmacologist can use to initially detect sensory system liabilities in standard IND enabling studies. The functional observational battery will be analyzed to highlight what behavioral endpoints may signal sensory system dysfunction or subliminal toxicity.  Based on these findings, we will provide further understanding and potential strategies to address some of the more common types of sensory pathology observed, clinical manifestations, and available Tier II evaluations related to vision, hearing, and balance assessments.  

CE Book   (Registration Required)


AM 3: Safety Pharmacologists - A Role as Detectives in Drug Discovery and Early Drug Development

Co-Chairs:  Tomas Mow, PhD, and Kristy D. Bruse, PhD, DSP

The role of the Safety Pharmacologist: How has the Safety Pharmacologist role changed over the last ten years?  To avoid costly late-stage failures, predictive safety assays and models have been implemented in earlier phases of the pharmaceutical R&D value chain. It is important that such a ‘frontloading paradigm’ is not only a ‘fail early strategy’. Since “sorting out” does not automatically secure identification of drug candidates with less safety liabilities. Such a ‘frontloading paradigm’ has to show the way toward ‘what will not fail’.

To do that safety assessment needs to be done in close collaboration with the other disciplines and should begin early by integrating information on the therapeutic target/patient population, chemistry, potency, selectivity, etc., etc. To secure such a strategy the Safety Pharmacologist has often shown to be the one with the right background and has been used to work in the interplay between chemistry, pharmacology, ADME and toxicology. There he/she has shown to be the key in deciphering liability signals during lead identification, lead optimization and candidate selection. The safety pharmacologist has often been the Program Manager’s “Best Friend”. 

This course will share current de-risking strategies including use of in silico modeling, in vitro, ex vivo and in vivo assessments including classical safety pharmacology studies - but also how to do safety assessment in efficacy, mini-toxicology or disease model studies will be addressed. The program will include basic background lectures within Cardiovascular, Respiratory and CNS liabilities and case stories. All with the focus on applicability of the assays and models in the “frontloading paradigm”.

CE Book   (Registration Required)


PM Courses


PM 1: In Silico Modeling of Proarrhythmia Risk

Co-Chairs:  Frederick Sannajust, PhD, and Anne S.Y. Chain, PhD

Recently, there is a paradigm shift in cardiotoxicity evaluation in drug development. The new emphasis is placed on qualifying and quantifying drug-induced pro-arrhythmic risk of novel compounds rather than the traditional hERG assessments.  Various working groups involving academicians, regulators and industry leaders have driven initiatives to propose and refine assays, decision algorithms, methodologies and clinical trial designs leading to the potential future replacement of the costly thorough-QT trials. 

The objective of this course is to present a selection of the latest approaches, research and findings in the evaluation of cardiac pro-arrhythmic risk during different stages of drug development. 

CE Book   (Registration Required)

PM 2: EEG Waveform Recognition Workshop

Co-Chairs:  Mary Jeanne Kallman and Carrie Markgraf

This workshop is a hands-on opportunity to become familiar with the technology and software for generating and interpreting electroencephalograms (EEG) in nonclinical species.  EEG is the gold standard for confirming seizure and for identifying sleep patterns and sleep disturbances.  However, reading nonclinical EEG waveforms and distinguishing abnormal from normal patterns is not a widely taught skill.  This hands-on workshop will give attendees a chance to work in small groups with an EEG expert to discuss and interpret real EEG data from multiple nonclinical species.  A training certificate, indicating that the attendee has been trained in basic EEG reading and interpretation will be issued for those who complete the workshop.


PM 3: Supplemental Safety Pharmacology

Co-Chairs:  Greet Teuns and Gouri Shankar Bhattacharyya

Supplemental Safety Pharmacology Studies, as stated in the S7A (section 2.8.2), are those studies that evaluate potential adverse pharmacodynamics effects on organ system functions which are not addressed by the core battery (CV, CNS, Resp) or by regular repeated dose toxicity studies.

This course will focus on safety pharmacology in metabolism pharmacology, renal safety pharmacology and on the use of diseased models in safety pharmacology.

CE Book   (Registration Required)




Safety Pharmacology Society | 11190 Sunrise Valley Dr, Suite 300 | Reston, VA 20191 | USA
Fax: 703.438.3113 | Email: SPS Headquarters | Voice: 703.547.0874
Site Map | Contact SPS | Privacy Policy and Disclaimer
SPS Copyright 2015. All Rights Reserved.